Form4insider filings, from the source

SEC Form 3 · accession 0000899243-18-027714

Axonics Modulation Technologies, Inc. · AXNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Karen Noblett
Officer — Chief Medical Officer
Period of report
Oct 30, 2018
Accepted (ET)
Oct 30, 2018 · 9:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001603756

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1holding———39,720D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1,F2$0.97holding————Oct 1, 2025Common Stock7,200—D
Stock Option (Right to Buy)F1,F3$0.98holding————Jan 15, 2026Common Stock9,600—D
Stock Option (Right to Buy)F1,F4$1.32holding————May 23, 2027Common Stock701—D
Stock Option (Right to Buy)F1,F5$1.32holding————Jul 5, 2027Common Stock390—D
Stock Option (Right to Buy)F1,F6$1.42holding————Aug 25, 2027Common Stock710—D
Stock Option (Right to Buy)F1,F7$1.63holding————Mar 30, 2028Common Stock18,000—D

Explanation of responses

Remarks

Exhibit List: Exhibit 24.1 - Power of Attorney